THERAPY DOSSIER · th-6c0f2c2ec985

SPA-DXM-NLP, a dexamethasone sodium phosphate nanoliposome conjugated to pulmonary surfactant protein A polyclonal antibody (mean particle size 136 plus or minus 38 nm, encapsulation efficiency 92 plus or minus 3 per cent)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23516459 ↗2013Reported benefit

Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats.

RatChemical/toxinSprague-Dawley (specific pathogen free)Malen = Therapeutic study of 60 rats in six groups of 10, split int…Intravenous (tail vein)1 mg/kg and 0.5 mg/kg dexamethasone sodium phosphate equiva…Started after establishment of the injury model

Model: Bleomycin-induced acute lung injury by endotracheal injection of 5 mg/kg bleomycin; the survival study used 10 mg/kg endotracheally

SPA-DXM-NLP gave 5.1-fold higher peak lung dexamethasone and 40.2-fold higher lung AUC than free dexamethasone and, at two weeks, improved lung injury scores, lowered bronchoalveolar TNF-alpha and TGF-beta1, eliminated positive cultures and raised 8 week survival to 83.3 per cent versus 33.3 per ce…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…